Ovid Therapeutics (OVID) Depreciation & Amortization (CF) (2016 - 2026)

Ovid Therapeutics (OVID) has reported Depreciation & Amortization (CF) for 11 consecutive years, with $16000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Depreciation & Amortization (CF) fell 83.84% year-over-year to $16000.0; the trailing twelve-month figure through Jun 2026 stood at $84000.0 (down 85.24% YoY), and the FY2025 full-year result was $273000.0, down 55.46% from the prior year.
• Depreciation & Amortization (CF) declined to $16000.0 in Q2 2026 per OVID's latest filing, from $35000.0 in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $184980.0 in Q4 2022 and bottomed at $16000.0 in Q3 2025.
• Historically, Depreciation & Amortization (CF) has averaged $112083.6 across 5 years, with a median of $138500.0 in 2023.
• The sharpest annual moves came in 2022 and 2025: Depreciation & Amortization (CF) jumped 224.81% in 2022, then plunged 90.53% in 2025.
• Over 5 years, Depreciation & Amortization (CF) stood at $184980.0 in 2022, then slipped by 24.32% to $140000.0 in 2023, then gained by 14.29% to $160000.0 in 2024, then sank by 89.38% to $17000.0 in 2025, then declined by 5.88% to $16000.0 in 2026.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $16000.0, $35000.0, and $17000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.